Elin Lindhagen
Medical Products Agency(SE)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Chronic Myeloid Leukemia Treatments, Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, Drug Transport and Resistance Mechanisms
Most-Cited Works
- → The fluorometric microculture cytotoxicity assay(2008)235 cited
- → In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues(2011)38 cited
- → Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia(2008)30 cited
- → Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo(2004)26 cited
- → The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing(2010)24 cited
- → Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo(2004)24 cited
- → Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cellsin vitro, as single agent and in drug combination(2008)22 cited
- → In vitro activity of bortezomib in cultures of patient tumour cells—potential utility in haematological malignancies(2008)18 cited
- → The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia(2012)17 cited
- → R-etodolac (SDX-101) and the related indole–pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells(2006)16 cited